Aripiprazole metabolic pathway (Homo sapiens)
From WikiPathways
Description
No description
Quality Tags
Ontology Terms
Bibliography
- Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, Azuma J; ''Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.''; Drug Metab Pharmacokinet, 2005 PubMed Europe PMC Scholia
- Spina E, de Leon J; ''Metabolic drug interactions with newer antipsychotics: a comparative review.''; Basic Clin Pharmacol Toxicol, 2007 PubMed Europe PMC Scholia
- Molden E, Lunde H, Lunder N, Refsum H; ''Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.''; Ther Drug Monit, 2006 PubMed Europe PMC Scholia
- Swainston Harrison T, Perry CM; ''Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.''; Drugs, 2004 PubMed Europe PMC Scholia
- Argo TR, Carnahan RM, Perry PJ; ''Aripiprazole, a novel atypical antipsychotic drug.''; Pharmacotherapy, 2004 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
Name | Type | Database reference | Comment |
---|---|---|---|
Aripiprazole | Metabolite | HMDB05042 (HMDB) | |
CYP2D6 | GeneProduct | ENSG00000100197 (Ensembl) | |
CYP3A43 | GeneProduct | ENSG00000021461 (Ensembl) | |
Product | Metabolite |
Annotated Interactions
No annotated interactions